Profil
Nicholas Mark Barnes is the founder of Celentyx Ltd., a company founded in 2004.
He holds the title of Chief Executive Officer & Director at Celentyx Ltd.
Mr. Barnes is currently the Chairman of the 5 HT Receptor Nomenclature Committee at The International Union of Basic & Clinical Pharmacology.
He is also a Professor at the University of Birmingham, a position he has held since 2012.
Postes actifs de Nicholas Mark Barnes
| Sociétés | Poste | Début |
|---|---|---|
Celentyx Ltd.
 Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Fondateur | 01/01/2004 |
| University of Birmingham | Corporate Officer/Principal | - |
| The International Union of Basic & Clinical Pharmacology | Corporate Officer/Principal | 04/04/2014 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Health Technology |
| The International Union of Basic & Clinical Pharmacology |
